A carregar...
Impaired wound healing secondary to bevacizumab
Bevacizumab is a monoclonal antibody that exerts its antitumor activity by inhibiting vascular endothelial growth factor. Consequently, it suppresses endothelial cell proliferation, vascular permeability, and angiogenesis. This inhibitory effect contributes to tumour size reduction but causes wound‐...
Na minha lista:
| Publicado no: | Int Wound J |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Publishing Ltd
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7948921/ https://ncbi.nlm.nih.gov/pubmed/31111622 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/iwj.13139 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|